The Dawn of a New Pharmaceutical Epoch: Can AI and Robotics Reshape Drug Formulation?

Pauric Bannigan,Riley J. Hickman,Alán Aspuru‐Guzik,Christine Allen

DOI: https://doi.org/10.1002/adhm.202401312

IF: 10

2024-08-19

Advanced Healthcare Materials

Abstract:Over four decades, pharmaceutical R&D expenditures have risen 51‐fold, yet clinical success rates stagnate at 10% due to efficacy and safety issues. This article proposes AI and automation to revolutionize drug formulation, optimizing development, reducing costs, and enhancing patient‐centered outcomes, ultimately increasing the success rates of new treatments. Over the last four decades, pharmaceutical companies' expenditures on research and development have increased 51‐fold. During this same time, clinical success rates for new drugs have remained unchanged at about 10 percent, predominantly due to lack of efficacy and/or safety concerns. This persistent problem underscores the need to innovate across the entire drug development process, particularly in drug formulation, which is often deprioritized and under‐resourced.

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials